Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNOVALYTE IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SYNOVALYTE is a hyaluronan preparation that acts as a viscoelastic supplement, restoring the rheological properties of synovial fluid in osteoarthritic joints. It provides lubrication and shock absorption, and may exert anti-inflammatory and analgesic effects through modulation of synovial fluid viscosity and interaction with hyaluronan receptors.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intra-articular injection: 2 m L per joint once weekly for 3 weeks.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable; components (sodium, chloride, lactate) are endogenous and rapidly redistributed; lactate half-life ~5-10 minutes in normal hepatic function.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Hyaluronan is primarily metabolized in the liver and synovium via hyaluronidases and subsequent breakdown into constituent monosaccharides.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Renal excretion of sodium, chloride, and lactate; not metabolized; elimination routes not quantified as it is a crystalloid solution.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Not bound; sodium, chloride, and lactate are free in plasma.
Negligible for electrolytes and dextrose (<5%).
Sodium and chloride distribute in extracellular fluid (Vd ~0.2 L/kg); lactate distributes in total body water (Vd ~0.6 L/kg).
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100% (by definition); not administered by other routes.
Intravenous: 100%.
No dosage adjustment required in renal impairment.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No dosage adjustment required in hepatic impairment.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Safety and efficacy not established in pediatric patients.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
No specific dosage adjustment required; use caution due to potential comorbidities.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Do not use in patients with known hypersensitivity to hyaluronan preparations.,Post-marketing reports of anaphylactoid reactions, including cases of cardiac arrest and death.,Use caution in patients with active joint infections or skin diseases at the injection site.,Effusion may occur post-injection; warn patients to avoid strenuous activities for 48 hours.,Repeated intra-articular injections may increase risk of adverse events.
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Known hypersensitivity to hyaluronate preparations.,Active joint infection or skin infection at the injection site.
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No known food interactions. Maintain normal diet unless instructed otherwise by physician.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
No teratogenic risk expected as Synovalyte (hyaluronate sodium) is a large molecular weight polysaccharide that does not cross the placenta. No fetal risk identified in animal studies.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Not expected to be excreted in breast milk due to high molecular weight. M/P ratio not available; use with caution in nursing mothers.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No dose adjustment required as pharmacokinetics are not altered by pregnancy; systemic absorption is negligible.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
Synovalyte in plastic container is a sterile, non-pyrogenic irrigating solution for intraoperative joint irrigation. Use only if solution is clear and container undamaged. Discard any unused portion; no preservatives. Monitor for fluid overload in patients with renal impairment or heart failure. Do not administer intravenously.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This solution is used during surgery to wash the joint area.,You may experience temporary swelling or discomfort after irrigation.,Report any signs of infection like increased pain, redness, or fever.,Follow your surgeon's post-operative instructions carefully.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNOVALYTE IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SYNOVALYTE IN PLASTIC CONTAINER is a Electrolyte Solution that works by SYNOVALYTE is a hyaluronan preparation that acts as a viscoelastic supplement, restoring the rheological properties of synovial fluid in osteoarthritic joints. It provides lubrication and shock absorption, and may exert anti-inflammatory and analgesic effects through modulation of synovial fluid viscosity and interaction with hyaluronan receptors.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNOVALYTE IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNOVALYTE IN PLASTIC CONTAINER is: Intra-articular injection: 2 m L per joint once weekly for 3 weeks.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNOVALYTE IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNOVALYTE IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk expected as Synovalyte (hyaluronate sodium) is a large molecular weight polysaccharide that does not cross the placenta. No fetal risk identified in animal stud. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.